Tofacitinib (Standard)
Based on 1 Customer Validation
Tofacitinib (Standard) is the analytical standard of Tofacitinib. This product is intended for research and analytical applications. Tofacitinib is an orally available JAK3/2/1 inhibitor with IC50s of 1, 20, and 112 nM, respectively.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.96%
- CAS. Nr.: 477600-75-2
- Formel: C16H20N6O
- Molecular Weight:312.37
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Product Information
-
Chemical Information
- Reinheit & Dokumentation
-
Help & FAQs
-
HY-50856R
Ruxolitinib (Standard)
-
HY-15315R
Baricitinib (Standard)
-
HY-19569
Upadacitinib
-
HY-19569R
Upadacitinib (Standard)
-
HY-40354
Tofacitinib
-
HY-50856
Ruxolitinib
-
HY-15315
Baricitinib
-
HY-50856A
Ruxolitinib (S enantiomer)
-
HY-19568
Peficitinib
-
HY-10409
Fedratinib
-
HY-107429
Abrocitinib
-
HY-18300
Filgotinib
Product Information
The compound is the grade of analytical standard, which is the reference standard supplied assay. It is commonly used in qualitative, quantitative and methodological research experiments in HPLC, GC and MS.
Chemical Information
-
CAS. Nr. 477600-75-2
-
Appearance Solid
-
Molecular Weight 312.37
-
Formel C16H20N6O
-
Color White to off-white
-
SMILES
O=C(CC#N)N1C[C@H](N(C2=C3C(NC=C3)=NC=N2)C)[C@H](C)CC1
-
Synonyms
Tasocitinib (Standard); CP-690550 (Standard)
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Jiang JK, et al. Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550). J Med Chem. 2008 Dec 25;51(24):8012-8. [Content Brief]
[2]. Onda M, et al. Tofacitinib suppresses antibody responses to protein therapeutics in murine hosts. J Immunol. 2014 Jul 1;193(1):48-55. [Content Brief]
[3]. LaBranche TP, et al. JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012 Nov;64(11):3531-42. [Content Brief]
[4]. Calama E, et al. Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS. Pulm Pharmacol Ther. 2017 Apr;43:60-67. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Tofacitinib (Standard) Related Classifications
HY-40354R Related Classifications
Powered by Bioz